Biotech | December 05, 2021
SPARC to licence Biomodifying’s IP
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
The offline store launch will complement the E-commerce website in building a rich consumer shopping experience
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Owkin builds best-in-class predictive biomedical AI models and robust data sets
The main objective of successive rounds of the NFHS is to provide reliable and comparable data relating to health and family welfare and other emerging issues
Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC
The 50-bed hospital is positioned to address complexities specific to women and children, going beyond a birthing facility
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
Subscribe To Our Newsletter & Stay Updated
